Related Experiment Video
Updated: Mar 7, 2026
Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing
Published on: October 10, 2025
Comprehensive profiling and quantitation of oncogenic mutations in non-small cell lung carcinoma using
Jian Shi1, Meng Yuan2, Zhan-Dong Wang3
11 Department of Medical Oncology, Fourth Hospital of Hebei Medical University, Shijiazhuang, China.
Abstract:
The carcinogenesis of non-small cell lung carcinoma has been found to associate with activating and resistant mutations in the tyrosine kinase domain of specific oncogenes. Here, we assessed the type, frequency, and abundance of epithelial growth factor receptor, KRAS, BRAF, and ALK mutations in 154 non-small cell lung carcinoma specimens using single-molecule amplification and re-sequencing technology. We found that epithelial growth factor receptor mutations were the most prevalent (44.2%), followed by KRAS (18.8%), ALK (7.8%), and BRAF (5.8%) mutations. The type and abundance of the mutations in tumor specimens appeared to be heterogeneous. Thus, we conclude that identification of clinically significant oncogenic mutations may improve the classification of patients and provide valuable information for determination of the therapeutic strategies.
Insights
Activating oncogene mutations drive non-small cell lung carcinoma. Researchers found epithelial growth factor receptor mutations most common, informing personalized lung cancer treatment strategies.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Carcinogenesis of non-small cell lung carcinoma (NSCLC) is linked to oncogenic mutations.
- Activating and resistant mutations in tyrosine kinase domains are key drivers.
Purpose of the Study:
- To determine the type, frequency, and abundance of specific oncogenic mutations in NSCLC.
- To investigate mutations in epithelial growth factor receptor (EGFR), KRAS, BRAF, and ALK.
Main Methods:
- Analysis of 154 NSCLC specimens.
- Utilized single-molecule amplification and re-sequencing technology.
Main Results:
- EGFR mutations were most prevalent (44.2%).
- KRAS mutations occurred in 18.8%, ALK in 7.8%, and BRAF in 5.8%.
- Observed heterogeneity in mutation type and abundance within tumor specimens.
Conclusions:
- Identification of clinically significant oncogenic mutations is crucial for NSCLC.
- Mutation profiling can improve patient classification and guide therapeutic strategies.
More Related Videos
07:59Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
11:20Simple and Rapid Method to Obtain High-quality Tumor DNA from Clinical-pathological Specimens Using Touch Imprint Cytology
Published on: March 21, 2018